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p27Kip1 ubiquitination and degradation is regulated by the
SCFSkp2 complex through phosphorylated Thr187 in p27
Lyuben M. Tsvetkov, Kun-Huei Yeh, Soo-Jung Lee, Hong Sun and Hui Zhang
Many tumorigenic processes affect cell-cycle progression
by their effects on the levels of the cyclin-dependent
kinase inhibitor p27Kip1 [1,2]. The phosphorylation- and
ubiquitination-dependent proteolysis of p27 is implicated
in control of the G1–S transition in the cell cycle [3–6]. To
determine the factors that control p27 stability, we
established a cell-free extract assay that recapitulates the
degradation of p27. Phosphorylation of p27 at Thr187 was
essential for its degradation. Degradation was also
dependent on SCFSkp2, a protein complex implicated in
targeting phosphorylated proteins for ubiquitination
[7–10]. Immunodepletion of components of the complex —
Cul-1, Skp1, or Skp2 — from the extract abolished p27
degradation, while addition of purified SCFSkp2 to Skp2-
depleted extract restored the capacity to degrade p27. A
specific association was observed between Skp2 and a
p27 carboxy-terminal peptide containing phosphorylated
Thr187, but not between Skp2 and the non-
phosphorylated peptide. Skp2-dependent associations
between Skp1 or Cul-1 and the p27 phosphopeptide were
also detected. Isolated SCFSkp2 contained an E3 ubiquitin
ligase activity towards p27. Our data thus suggest that
SCFSkp2 specifically targets p27 for degradation during
cell-cycle progression.
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Results and discussion
Selective p27 degradation in cell-free systems has been
reported previously in synchronized S-phase cell extracts
but not in G1 extracts [6,11]. To identify the proteins that
control p27 stability, we prepared a cytosolic extract from
asynchronized and exponentially growing HeLa cells.
When recombinant 35S-labeled p27 was incubated with
this extract, p27 was quite stable, even upon prolonged
incubation. Addition of an active Cdk2–cyclin E kinase to
the extract led to the rapid degradation of p27 (Figure 1a,b
and see Supplementary material published with this article
on the internet). The requirement for Cdk2–cyclin E in
p27 destruction is probably due to its ability to phosphory-
late p27 at Thr187, which has been shown to trigger p27
degradation [4,5]. Indeed, conversion of Thr187 to glycine
(T187G) stabilized p27 in the extract (Figure 1a). In the
presence of Cdk2–cyclin E, a fraction of p27 slightly
shifted its electrophoretic mobility. This fraction was sensi-
tive to phosphatase (Figure 1c), suggesting that it contains
phosphorylated forms of p27. 
Another fraction of p27 was converted into multiple high-
molecular-weight phosphatase-insensitive species in the
presence of Cdk2–cyclin E (Figure 1c). Addition of spe-
cific inhibitors of the 26S proteasome, such as MG132, sta-
bilized p27 and caused the accumulation of both the
phosphorylated and the high-molecular-weight forms
(Figure 1c). Modified ubiquitins such as methyl ubiquitin
and ubiquitin aldehyde also caused accumulation of p27
ladders (Supplementary material, Figure S1b). This is
likely to be due to their interference with the degradation
rate of highly polyubiquitinated proteins and their inhibi-
tion of de-ubiquitination [12]. These observations indicate
that the high-molecular-weight species of p27 are the
polyubiquitinated forms. Thus our in vitro system faith-
fully recapitulated ubiquitin-dependent degradation of
p27 in a Cdk2–cyclin E-dependent process that requires
phosphorylation of the Thr187 residue in p27.
Using the in vitro p27 degradation system, we examined
the involvement of the candidate ubiquitin E3 ligase the
SCF complex — Skp1/Cdc53(Cullins)/F-box proteins —
in p27 degradation. SCF complexes represent a conserved
family of protein complexes that target phosphorylated
proteins for ubiquitin-dependent proteolysis [13,14]. We
first examined whether Cul-1, a human Cdc53 homolog, is
required for p27 degradation [8–10]. Cul-1 was depleted
from the HeLa cell extracts by passage through an affin-
ity-purified anti-Cul-1 antibody column. Depletion of
Cul-1 abolished the ability of the extracts to degrade p27,
whereas parallel mock depletion using purified IgG from
pre-immune serum had no effect (Figure 2a). Western
blotting confirmed the removal of Cul-1 from the extracts
(Figure 2d). Immunodepletion of another component of
the SCF complex, Skp1 [7,15], also inhibited p27 degrada-
tion (Figure 2b,d). 
The requirement for Cul-1 and Skp1 in p27 degradation
implies that an F-box protein is also involved. The F-box
protein is a component of the SCF complex that interacts
directly with the phosphorylated substrate, thus defining
the substrate specificity for ubiquitination [14]. To iden-
tify the F-box protein(s) that specifically binds to p27,
35S-labeled HeLa cell extracts were incubated with
GST–p27 fusion protein either with or without prior phos-
phorylation by Cdk2–cyclin E. Examination of the labeled
proteins specifically associated with the phosphorylated
GST–p27 beads revealed the presence of a protein of mol-
ecular weight 45 kDa, similar to that of the F-box protein
Skp2 (data not shown). To determine whether Skp2 is
involved in p27 degradation, HeLa extracts were depleted
of Skp2 using an affinity-purified anti-Skp2 antibody
column. Degradation of p27 was inhibited in the immuno-
depleted extracts (Figure 2c,d).
To directly examine the specific binding of Skp2 to
phosphorylated p27, we synthesized a pair of peptides
corresponding to the carboxy-terminal end of p27 (amino
acids 175–198). One (p27CP) contains phosphorylated
Thr187 and the other (p27C) unphosphorylated Thr187
(Figure 3a). The peptides were each coupled to Sulfo-
Link agarose beads, which were then used as affinity
resins for binding analysis of F-box proteins. We initially
tested whether these peptides could interact with several
known F-box proteins, including Skp2, β-TrCP and
MD6, as well as with a number of unpublished ones that
we identified by searching expressed sequence tag
(EST) databases. F-box proteins that had been translated
and 35S-labeled in vitro were incubated with the p27
peptide beads. Analysis of the F-box proteins associated
with p27 peptide beads revealed a specific interaction
between Skp2 and p27CP but not p27C (Figure 3b). We
did not detect specific associations between p27CP and
other available F-box proteins (Figure 3b and data not
shown). These results suggest that Skp2 interacts selec-
tively and specifically with p27CP.
To determine whether endogenous Skp2 in the HeLa
extract can also interact with p27CP, the peptide beads
were incubated with the extracts. Western blot analysis
detected a strong and specific interaction between
endogenous Skp2 and p27CP (Figure 3c). p27C did not
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Figure 1
Phosphorylation-dependent p27 degradation
in HeLa extracts. (a) 35S-labeled p27 or p27
T187G mutant was incubated with HeLa
extract (Ext) for 3 h at 30°C. Cdk2–cyclin E
(Cdk2–E) or MG132 (20 µM) were added as
indicated. The p27 reaction products were
isolated by immunoprecipitation. (b) Time
course of p27 degradation in the extracts.
(c) p27 was incubated with HeLa extracts in
the absence or presence of Cdk2–cyclin E
and MG132. The reaction products were
treated with lambda phosphatase (PPTase).
The phosphorylated and high-molecular-
weight p27 species (in brackets) are
indicated.
Ext
Cdk2–E
MG132
Ext
Cdk2–E
MG132
PPTase
–
–
–
+
–
–
p27(a)
(b)
(c)p27 T187G
+ Cdk2–E
–p27
p27
Current Biology   
p27–P–p27
+
+
–
+
+
+
–
–
–
+
–
–
+
+
–
+
1 2 3 4 5 6 7 8
+
+
–
–
–
+
–
–
+
+
–
+
+
+
+
+
+
– – – – +
Inp
ut
Ex
t
0 
h
1 
h
3 
h
Figure 2
Inhibition of p27 degradation by depletion of SCFSkp2. HeLa extracts
(ext) were passed through affinity-purified (a) anti-Cul-1, (b) anti-Skp1
or (c) anti-Skp2 antibody columns. Control depletions were conducted
using a purified immunoglobulin G (IgG) column. The control and Cul-
1-depleted extracts were assayed for p27 degradation activity in the
presence of Cdk2–cyclin E (Cdk2–E) for 3 h or for various times as
indicated. Lanes 1–3 show results with p27 alone and undepleted
HeLa extracts as indicated. Reaction products were treated with
lambda phosphatase except in (b). Dep, depleted. (d) Specific removal
of Skp2, Skp1 and Cul-1 by immunodepletion. Untreated HeLa extract,
control depleted, and Skp2-, Skp1-, or Cul-1-depleted extracts were
western blotted by anti-Skp2 (top), anti-Skp1 (middle) or anti-Cul-1
(bottom) antibodies. Ab, antibody used for depletion.
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interact with Skp2 significantly. As a control for Skp2
binding, we also assayed for the binding of the F-box
protein β-TrCP [14] to the p27 peptides, and found no
interaction (Figure 3c). 
Previous studies indicated that Skp2 interacts with Skp1
and Cul-1 in vivo [8–10]. In the HeLa extract, such inter-
actions were also detected (Figure 3d). Using the peptide
bead pull-down assays, we also detected specific interac-
tion of Skp1 or Cul-1 with p27CP beads but not with
p27C beads (Figure 3c). We then carried out assays for
Skp1 or Cul-1 binding to p27 peptides in Skp2-depleted
extracts. Depletion of Skp2 greatly reduced the binding of
Skp1 (Figure 3e) or Cul-1 (data not shown) to p27CP
beads, although the total levels of Skp1 and Cul-1 in the
Skp2-depleted extract were not substantially altered
(Figure 3e and data not shown). These studies suggest
that Skp2 is the SCF component that binds to the phos-
phorylated Thr187 of p27. Upon binding to phosphory-
lated p27, Skp2 brings in its associated Skp1 and Cul-1
which targets p27 for degradation through the proteasome.
We further investigated whether addition of SCFSkp2 to
the Skp2-depleted extract could restore p27 degradation
activity. Recombinant SCFSkp2 was expressed and assem-
bled using the baculovirus expression system and purified.
When recombinant SCFSkp2 was added back to the Skp2-
depleted extract, p27 degradation capacity was restored
(Figure 4a). This restoration depended on the presence of
Skp2 in the complex; complexes assembled in the absence
of Skp2 could not rescue the Skp2 deficiency in the
extract. Addition of purified Skp2 alone could partially
rescue p27 degradation in the Skp2-depleted extract (data
not shown), but the assembled SCFSkp2 complex consis-
tently produced better restoration, indicating that the
complex is required for p27 degradation. 
p27 ubiquitination was also assayed directly using recom-
binant SCFSkp2. In a purified system containing recombi-
nant SCFSkp2, Cdk2–cyclin E, ubiquitin-activating
enzyme E1 and ATP, a fraction of p27 was converted
into multiple high-molecular-weight species (Figure 4b).
The formation of high-molecular-weight p27 depended
on the presence of ubiquitin and Cdc34, a conserved E2
conjugating enzyme that is implicated in SCF-mediated
ubiquitination [9,13]. These data suggest that SCFSkp2
can ubiquitinate p27 in the presence of E1 and E2.
However, p27 ubiquitination using the purified proteins
was not very efficient. It is possible that SCFSkp2 may
require additional modifications or activities for efficient
p27 ubiquitination.
Our results strongly suggest that SCFSkp2 specifically
binds to the Thr187-phosphorylated form of p27 and
targets it for degradation through a ubiquitin-dependent
process. These results are consistent with our previous
observation that Skp2 regulates a critical event during the
G1–S transition [7]. Skp2 level is elevated during late G1
and S phase [7,9], suggesting that Skp2 is probably rate-
limiting for the assembly and activation of SCFSkp2.
However, p27 regulation could occur at several levels in
vivo, including cellular compartmentalization, alternative
degradation pathway(s), and sequestration of p27 by cyclin
D complexes [1,16,17]. Some of these controls may be
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Figure 3
Specific interactions between SCFSkp2 and the Thr187-phosphorylated
p27 peptide (p27CP). (a) Sequences of p27 carboxy-terminal peptides
(residues175–198) with (p27CP) or without (p27C) Thr187
phosphorylation. (b) Skp2 specifically binds to p27CP. 35S-labeled F-
box proteins, Skp2, β-TrCP, and MD6 (10 µl each) were incubated for
1 h with p27C beads or p27CP beads and proteins associated with the
beads were purified and analyzed. IVT, in vitro translated input protein.
(c) Selective binding of Skp2, Skp1 and Cul-1 to p27CP in HeLa
extracts. HeLa extracts (400 µg) were incubated with p27CP beads or
p27C beads for 1 h. The proteins associated with the beads were
analyzed by western blotting with either anti-Skp2, anti-Skp1, anti-Cul-1
or anti-β-TrCP antibodies, as indicated. Immunoprecipitated Skp2, Skp1
and Cul-1 (IP) are included as controls (lane 4), as are pre-immune
samples (pre; lane 3). For lane 4 of β-TrCP, HeLa extracts (25 µg) were
directly loaded without immunoprecipitation. The amounts of HeLa
extract for Skp2 immunoprecipitation were 25 µg and 100 µg for Skp1
and Cul-1, respectively. (d) Association between Skp1, Skp2 and Cul-1
in HeLa extracts. Skp1, Skp2 and Cul-1 complex were
immunoprecipitated by specific antibodies as indicated. Skp2 was
detected among the immunoprecipitated proteins by western blotting
with anti-Skp2 antibodies. (e) Association between Skp1 and p27CP
depends on the presence of Skp2. Undepleted HeLa extracts (none),
mock-depleted or Skp2-depleted extracts (100 µg each) were incubated
with either p27C beads or p27CP beads. Skp1 (bottom) or Skp2 (top)
associated with the peptide beads was detected by western blotting.
Skp2 and Skp1 in the mock- and Skp2-depleted extracts (25 µg each)
were also detected by direct western blotting (lanes 7,8).
(b)
(d) (e)
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cell-type specific [1,2]. This may in part explain why we
have previously failed to detect a change in total p27
levels in several cancer cell lines using antisense oligo-
nucleotides against the components of SCF [8]. Our
present finding that SCFSkp2 is involved in targeting p27
for degradation might help to explain why Skp2 is highly
induced in many transformed cells [7] and may provide a
mechanism for the enhanced p27 degradation activity or
altered p27 levels associated with many cancers [1,2].
Supplementary material
Additional methodological details and figures are published with this
paper on the internet.
Acknowledgements
This work is supported by a grant (CA72878 to H.Z.) from the National
Cancer Institute, National Institutes of Health. H.S. is a Pew Scholar in Bio-
medical Sciences. The work was initiated by the support of the Donaghue
Medical Research Foundation in Connecticut (DF96–130 to HZ). K-H.Y. is
a recipient of a fellowship from the National Health Research Institute,
Taiwan. We thank Arthur Haas and Michele Pagano for E1 and Cdc34
cDNAs and useful information on reagents.
References
1. Clurman BE, Porter P: New insights into the tumor suppression
function of p27. Proc Natl Acad Sci USA 1998, 95:15158-15160.
2. Li DM, Sun H: PTEN/MMAC1/TEP1 suppresses the tumorigenicity
and induces G1 cell cycle arrest in human glioblastoma cells.
Proc Natl Acad Sci USA 1998, 95:15406-15411.
3. Pagano M, Tam SW, Theodoras, AM, Beer-Romero P, Del Sal G,
Chau V, et al.: Role of the ubiquitin-proteasome pathway in
regulating abundance of the cyclin-dependent kinase inhibitor
p27. Science 1995, 269:682-685.
4. Sheaff RJ, Groudine MMG, Roberts JM, Clurman BE: Cyclin E-CDK2
is a regulator of p27Kip1. Genes Dev 1997 11:1464-1178.
5. Vlach J, Hennecke S, Amati B: Phosphorylation-dependent
degradation of the cyclin-dependent kinase inhibitor p27. EMBO J
1997, 16:5334-5344.
6. Nguyen H, Gitig DM, Koff A: Cell-free degradation of p27(kip1), a
G1 cyclin-dependent kinase inhibitor, is dependent on CDK2
activity and the proteasome. Mol Cell Biol 1999, 19:1190-1201.
7. Zhang H, Kobayashi R, Galaktionov K, Beach D: p19Skp1 and
p45Skp2 are essential elements of the cyclin A-CDK2 S phase
kinase. Cell 1995, 82:915-925.
8. Yu ZK, Gervais JL, Zhang H: Human CUL-1 associates with the
Skp1/Skp2 complex and regulates p21(CIP1/WAF1) and cyclin D
proteins. Proc Natl Acad Sci USA 1998, 95:11324-11329.
9. Lisztwan J, Marti A, Sutterluty H, Gstaiger M, Wirbelauer C, Krek W:
Association of human CUL-1 and ubiquitin-conjugating enzyme
CDC34 with the F-box protein p45(Skp2): evidence for
evolutionary conservation in the subunit composition of the
CDC34-SCF pathway. EMBO J 1998, 17:368-383.
10. Lyapina SA, Correll CC, Kipreos ET, Deshaies RJ: Human CUL1
forms an evolutionarily conserved ubiquitin ligase complex (SCF)
with Skp1 and an F-box protein. Proc Natl Acad Sci USA 1998,
95:7451-7456.
11. Brandeis M, Hunt, T: The proteolysis of mitotic cyclins in
mammalian cells persists from the end of mitosis until the onset
of S phase. EMBO J 1996, 15:5280-5289.
12. Hershko A, Rose IA: Ubiquitin-aldehyde: a general inhibitor of
ubiquitin-recycling processes. Proc Natl Acad Sci USA 1987,
84:1829-1833.
13. Patton EE, Willems AR, Tyers M: Combinatorial control in ubiquitin-
dependent proteolysis: don’t Skp the F-box hypothesis. Trends
Genet 1998, 14:236-243.
14. Maniatis T: A ubiquitin ligase complex essential for the NF-B,
Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev
1999, 13:505-510.
15. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ:
Skp1 connects cell cycle regulators to the ubiquitin proteolysis
machinery through a novel motif, the F-box. Cell 1996,
86:263-274.
16. Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-
dependent kinase and titration of p27Kip1 regulated by mitogen-
activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA
1998, 95:1091-1096.
17. Aktas H, Cai H, Cooper GM: Ras links growth factor signaling to
the cell cycle machinery via regulation of cyclin D1 and the Cdk
inhibitor p27KIP1. Mol Cell Biol 1997, 17:3850-3857.
664 Current Biology, Vol 9 No 12
Figure 4
SCFSkp2 contains an E3 ubiquitination activity that acts on p27.
(a) Restoration of p27 degradation activity in Skp2-depleted extracts
by recombinant SCFSkp2. Insect SF9 cells were co-infected with
baculoviruses encoding GST–Skp1 and Cul-1, either in the presence
or absence of Skp2-recombinant baculoviruses. The SCFSkp2 (SCF)
and SC (lacking Skp2) complexes formed were isolated by
glutathione–Sepharose. Recombinant SCFSkp2, SC (1 µg each in
2 µl), or buffer alone (2 µl) was added to the Skp2-depleted extracts
(200 µg) as indicated, and p27 degradation was assayed in the
presence of Cdk2–cyclin E. Undepleted HeLa extract (ext) was
included as the control. (b) Ubiquitination of p27 using recombinant
proteins. p27 was incubated with recombinant SCFSkp2 in the
presence of purified Cdk2–cyclin E and Cdk2–cyclin A kinases, human
E1 ubiquitin-activating enzyme, ATP, ubiquitin and recombinant
Cdc34, an E2 ubiquitin-conjugating enzyme (lane 2) as described in
Supplementary material. The reactions in lanes 3 and 4 were carried
out in the absence of ubiquitin or Cdc34, respectively.
(b)
   Current Biology   
+ 
SC
Skp2 dep
+ 
Bu
ffe
r
+ 
SC
F
Ex
t +
 C
dk
2–
E
Mo
ck
 de
p
Ex
t
p2
7 
inp
ut
(a)
1 2 3 4
SC
F–
Sk
p2
 +
 C
dc
34
SC
F–
Sk
p2
 +
 U
b
p2
7 
inp
ut
SC
F–
Sk
p2
 +
 C
dc
34
 +
 U
b
1 2 3 4
5 6 7
–p27
–p27
p27–Ub
p27Kip1 ubiquitination and degradation is regulated by the
SCFSkp2 complex through phosphorylated Thr187 in p27
Lyuben M. Tsvetkov, Kun-Huei Yeh, Soo-Jung Lee, Hong Sun and Hui Zhang
Current Biology 7 June 1999, 9:661–664
S1
Supplementary materials and methods
Recombinant proteins
Cyclin E, p27, Skp1 and Skp2 were each cloned into pVL1392
(PharMingen) vector as glutathione-S-transferase (GST) fusion pro-
teins. Human Cul-1, Skp2, and Skp1 cDNAs were also cloned directly
into baculovirus pVL1392 or pVL1393 expression vectors. The con-
struction of these baculoviruses was according to [S1]. The bac-
uloviruses for Cdk2 and GST–cyclin A were kindly provided by David
Morgan (UCSF) and Helen Piwnica-Worms (University of Washing-
ton, St Louis, USA) and have been described previously [S1]. The
cDNA clone encoding human E1 ubiquitin-activating enzyme was
kindly provided by Arthur Haas (Medical College of Wisconsin) and
was cloned into the baculovirus expression vector, pAcSG–His–NT
(PharMingen), as a His6-tagged protein. The E1 protein was
expressed in the baculovirus expression system and purified by ubiqui-
tin affinity chromatography [S2]. The purification was monitored by
protein staining and the E1 activity was assayed by covalent conjuga-
tion of biotinylated ubiquitin [S3]. For 35S-labeled p27, SF9 cells were
infected with baculoviruses encoding GST–p27. 40 h after infection,
cells were labeled with 35S-methionine for 3 h as described [S1]. The
labeled GST–p27 protein was isolated by glutathione–Sepharose
beads and the p27 portion was released from the beads by thrombin
treatment for 30 min at room temperature (Calbiochem) [S4]. Throm-
bin was subsequently inactivated by 1 mM phenylmethylsulfonyl fluo-
ride (PMSF). The purified p27 is monitored by autoradiography and
quantified by protein staining and western blot analysis. 
To assemble Cdk2–cyclin E, GST–cyclin E and Cdk2 baculoviruses
were individually expressed in SF9 cells. The lysates were made in
hypotonic buffer (20 mM Hepes pH 7.2, 5 mM KCl, 1.5 mM MgCl2,
0.5 mM dithiothreitol (DTT)). The lysates containing GST-cyclin E and
Cdk2 were mixed and incubated in the presence of 10 mM ATP at
30°C for 1 h to assemble the active Cdk2–cyclin E kinase. The kinase
was then affinity purified using the glutathione beads and quantified by
protein staining and western blotting. The activity of purified kinase was
monitored by the histone H1 assay [S1]. To produce SCFSkp2, bac-
uloviruses encoding GST–Skp1 and Cul-1, in the presence or absence
of baculoviruses encoding Skp2, were co-infected into insect SF9 cells
and were affinity purified using glutathione–Sepharose columns. The
successful assembly of the complex was monitored and quantified by
protein staining and western blotting. The in vitro translated proteins
were produced and labeled with [35S]methionine in TNT rabbit reticulo-
cyte lysates according to the manufacturer’s instructions (Promega).
The human Cdc34 cDNA clone was kindly provided by  Michele
Pagano (New York University Medical Center) and was cloned into
pGEXKG as a GST fusion protein and expressed in Escherichia coli
BL21. GST–Cdc34 was isolated by glutathione column and the GST
portion was removed by thrombin. The Cdc34 protein was further puri-
fied by Mono Q column and monitored by protein staining. The methyl
ubiquitin and ubiquitin aldehyde were purchased from BostonBiochem.
Cells and extracts
HeLa cells were grown in DMEM supplemented with 10% fetal bovine
serum at 37°C as previously described [S1]. For extract preparation, a
suspension of HeLa cells was grown to 0.5–1 × 106 cells per ml (log
phase) and extracts were made according to Brandeis and Hunt [S5]
with modification. Cell pellets were washed twice with PBS and then
with hypotonic buffer (see above). The cells were resuspended in two
volumes of hypotonic buffer. They were lysed by Dounce homogeniza-
tion using a loose pestle. The cytosolic extracts were prepared by cen-
trifugation at 15,000 rpm using a Sorvall SS34 rotor. Aliquots of the
extracts were immediately frozen in liquid nitrogen and kept at –80°C
until use. For a typical p27 degradation reaction, 200 µg cytosolic
extract was used in a total volume of 50 µl, with no more than 20% dilu-
tion of the extract. The reaction mixture also contained 2 mM ATP,
20 mM creatine phosphate, 50 µg/ml creatine kinase, 20 mM Hepes
pH 7.2, 1 mM DTT and 10 mM MgCl2. The reactions were initiated by
adding 35S-labeled p27 (2 µl of in vitro translated or 0.25–0.5 µg bac-
ulovirus-produced) and Cdk2–cyclin E (1–3 µg) and incubation at 30°C
for 1–3 h. The requirement for Cdk2–cyclin E was usually titrated batch-
wise for different extract preparations beforehand and we found that a
threshold level of Cdk2–cyclin E was required for p27 degradation. The
Supplementary material
Figure S1
Ubiquitination of p27 in HeLa cytosolic extracts. (a) Time course of
p27 degradation in extracts. The reaction products of p27 in Figure
1b were quantified and plotted. (b) Accumulation of ubiquitinated p27
in the presence of modified ubiquitins. p27 was incubated with HeLa
extract, Cdk2–cyclin E, and methyl ubiquitin (UbM, 0.5 µg/ml) and
ubiquitin aldehyde (UbA, 1 µM) as indicated. The ubiquitinated p27
ladders accumulated because methylated ubiquitin shortens the
polyubiquitinated chain and thus slows down the rate of degradation
while ubiquitin aldehyde inhibits de-ubiquitination of ubiquitinated
proteins by isopeptidases. The reactions were carried out as
described in Figure 1a.
(b)
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requirement for Cdk2–cyclin E is also dependent on the amount of
exogenously added p27, reflecting the fact that p27 serves both as an
inhibitor and a substrate for the kinase. A substantial amount of endoge-
nous p27 is present in the extract which is also degraded by addition of
Cdk2–cyclin E. The reactions were stopped by adding 0.1% SDS, fol-
lowed by addition of 1 ml NP-40 lysis buffer containing 20 mM Tris
pH 7.5, 150 mM NaCl, 0.5% NP-40, and in the presence of protease
inhibitors (5 µg/ml leupeptide, soybean trypsin inhibitor, aprotinin, and
100 mM benzamidine, all from Sigma). The reaction products were
immunoprecipitated by p27 antibodies, fractionated in SDS–PAGE, and
visualized by autoradiography. Degradation of endogenous p27 in the
extracts was monitored by directly loading onto an SDS–PAGE in the
SDS sample buffer, followed by western blotting with anti-p27 antibod-
ies. For the ubiquitination by recombinant proteins in Figure 4b, purified
and labeled p27 (0.2 µg) was incubated with recombinant SCFSkp2
(0.5 µg) in the presence of purified cyclin E and Cdk2–cyclin A kinases
(1 µg each), recombinant human E1 ubiquitin-activating enzyme
(0.5 µg), and recombinant Cdc34 (1 µg) in a reaction containing 20 mM
Hepes pH 7.2, 10 mM MgCl2, 2 mM ATP and 6 µM ubiquitin at 30°C
for 3 h. The reaction products were isolated by immunoprecipitation with
anti-p27 antibodies.
Antibodies and cDNA clones
Full-length GST–p27 was purified from bacteria and used as the
antigen for immunization of rabbits. The Skp1, Skp2, and Cul-1 anti-
bodies were described previously [S1,S6]. Other relevant antibodies
were purchased from commercial sources (Santa Cruz Biotechnology
and PharMingen). The rat anti-human β-TrCP antibody was kindly pro-
vided by Tian Xu (Yale University). The cDNA clones encoding F-box
proteins such as MD6 and β-TrCP were obtained from Research
Genetics and sequenced. Immunoprecipitation and western blot analy-
sis were conducted as described previously [S1]. 
Depletion of the SCF complexes from HeLa extracts
Cul-1, Skp1 and Skp2 antibodies were affinity purified using recombi-
nant proteins as antigens as described previously [S1]. Pre-immune
IgG was purified by Sepharose–protein A  beads (Pharmacia). For
depletion of Skp2, Cul-1 or Skp1 proteins from HeLa extracts, 4 mg of
affinity-purified antibodies or IgG were coupled to 1 ml
Sepharose–protein A column. HeLa extracts (5–10 ml) were passed
through the antibody–protein A column three times at 4°C. The
flowthrough fractions of the columns were collected and examined for
the efficiency of depletion using western blot analysis. They were then
used as depleted extracts. For restoration of p27 degradation activity in
Skp2-depleted extract, 2 µg purified Skp2, SCFSkp2 or SC (no Skp2)
complexes were added to Skp2-depleted extracts and the degradation
of p27 was monitored as described above. 
Peptide synthesis
Peptides containing the carboxy-terminal end of p27 (residues
175–198, 24mer) – either CSDGSPNAGSVEQTPKKPGLRRRQT, or
the same peptide phosphorylated on Thr187 (*T), CSDGSP-
NAGSVEQ*TPKKPGLRRRQT, were synthesized using the peptide
synthesis facility at the HHMI Biopolymer/W. M. Keck Biotechnology
Resource Laboratory at the Yale University School of Medicine. The
Thr187-phosphorylated and unphosphorylated forms of the p27
carboxy-terminal peptides were conjugated to SulfoLink beads (Pierce)
through the cysteine residue added at the amino terminus of the pep-
tides according to the manufacturer’s instruction (Pierce). For coupling
reactions, 0.5 mg peptide was conjugated onto 2 ml of Sulfolink beads
for 30 min and the residual sites on the beads were blocked by 20 mM
cysteine for 2 h at room temperature. The beads were washed exten-
sively with PBS and then hypotonic buffer. They were stored at 4°C.
For F-box-protein-binding assays, 10 µl of the in vitro translated F-box
proteins, including Skp2, β-TrCP, and MD6, were mixed with 20 µl
peptide beads in 250 µl NP-40 lysis buffer containing protease
inhibitors (5 µg/ml leupeptide, trypsin inhibitor, aprotinin and 100 µM
benzamidine) and 100 mM NaF. Binding assays were performed at
4°C for 1 h with end-to-end rotation. The beads were washed four
times with NP-40 buffer and the proteins associated with the beads
were analyzed. Similar procedures were used for the extract binding
except that 100–400 µg of HeLa extract was used as the source of
SCF complexes, replacing the in vitro translated F-box proteins.
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S2 Supplementary material
Figure S2
Time course of SCFSkp2-mediated restoration
of p27 degradation in Skp2-depleted extracts.
Mock- or Skp2-depleted HeLa extracts
(200 µg) were incubated with recombinant
SCFSkp2 (2 µg) and labeled p27 substrate
(0.25 µg) in the presence of Cdk2–cyclin E
(2 µg). The reactions were stopped at various
time points as indicated. The reaction
products were separated by SDS–PAGE and
visualized by autoradiography.
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